Avricore Health’s HealthTab™ Powers NHS Pilot for Cholesterol Management

Avricore Health ( (TSE:AVCR) ) has issued an announcement.

Avricore Health Inc. announced that its HealthTab™ platform is being deployed in a pilot program by Barts Health NHS Trust, in collaboration with UCL Partners and the British Heart Foundation, to deliver cholesterol-lowering inclisiran injections through community pharmacies in the UK. This initiative, supported by a £198,000 grant, marks a significant expansion of HealthTab’s role from screening to therapy-linked workflows, integrating with Ortus-iHealth to connect directly into hospital systems. This move is expected to strengthen Avricore’s position in the UK community pharmacy networks and align with NHS policies to decentralize cardiovascular therapy delivery, potentially impacting long-term lipid management and reducing hospital burdens.

Spark’s Take on TSE:AVCR Stock

According to Spark, TipRanks’ AI Analyst, TSE:AVCR is a Neutral.

Avricore Health’s strong financials and strategic corporate developments are offset by high valuation concerns and neutral technical indicators. The company’s financial stability and growth potential are promising, but profitability and valuation require attention.

To see Spark’s full report on TSE:AVCR stock, click here.

More about Avricore Health

Avricore Health Inc. is a pharmacy service innovator focused on developing early-stage technologies to advance pharmacy practice and patient care. Its flagship offering, HealthTab™, aims to create the world’s largest network of rapid testing devices in community pharmacies, making actionable health information more accessible.

Average Trading Volume: 60,272

Technical Sentiment Signal: Sell

Current Market Cap: C$5.57M

For a thorough assessment of AVCR stock, go to TipRanks’ Stock Analysis page.